Mystic Asset Management Inc. Sells 1,300 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mystic Asset Management Inc. reduced its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,940 shares of the specialty pharmaceutical company’s stock after selling 1,300 shares during the period. Mystic Asset Management Inc. owned 0.05% of Supernus Pharmaceuticals worth $747,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fidelis Capital Partners LLC purchased a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $33,000. Quadrant Capital Group LLC raised its stake in Supernus Pharmaceuticals by 1,117.6% during the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,330 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Supernus Pharmaceuticals in the first quarter worth $43,000. Meeder Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $47,000. Finally, Innealta Capital LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at $51,000.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $41.00 to $36.00 in a research note on Wednesday.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $31.11 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44. The stock has a fifty day simple moving average of $31.69 and a two-hundred day simple moving average of $30.41.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). The business had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. Supernus Pharmaceuticals’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.02) earnings per share. Analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.